Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
Lists
Only you see this
Abstract
Although time to CDP between groups was not significant, overall subgroup analyses suggest selective B-cell depletion may affect disease progression in younger patients, particularly those with inflammatory lesions.
BibTeX
@article{hawker2009rituximab,
author = {Kathleen Hawker and Paul O’Connor and Mark S. Freedman and Peter A. Calabresi and Jack P. Antel and Jack H. Simon and Stephen L. Hauser and Emmanuelle Waubant and Timothy Vollmer and Hillel Panitch and Jiameng Zhang and Peter Chin and Craig H. Smith and OLYMPUS trial group},
title = {{Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial}},
journal = {Annals},
year = {2009},
doi = {10.1002/ana.21867},
}Loading related content...